Alpha-9 Theranostics, a Vancouver, B.C. and Boston-based biotech company developing radiotherapies, raised $75 million. The company was founded by researchers from the University of British Columbia and BC Cancer, and is led by David Hirsch, a venture partner at Longitude Capital, which led a previous $11 million Series A funding round.
Read more about this at geekwire.com